Results 91 to 100 of about 60,513 (321)

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis

Hematology, 2022
Objectives Myelofibrosis is a rare bone marrow disorder associated with a high symptom burden, poor prognosis, and shortened survival. While allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for myelofibrosis, the ...
Timothy Devos, Dominik Selleslag, Nikki Granacher, Violaine Havelange, Fleur Samantha Benghiat   +4 more
doaj   +1 more source

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.

Blood Advances, 2020
PAC203 is a randomized dose-finding study of pacritinib, an oral JAK2/IRAK1 inhibitor, in patients with advanced myelofibrosis who are intolerant of or resistant to ruxolitinib.
A. Gerds, M. Savona, B. Scott, M. Talpaz, M. Egyed, C. Harrison, A. Yacoub, A. Vannucchi, A. Mead, J. Kiladjian, J. O'Sullivan, V. García‐Gutiérrez, P. Bose, R. Rampal, Carole B. Miller, J. Palmer, S. Oh, S. Buckley, D. Mould, Kaori Ito, Shanthakumar R. Tyavanagimatt, Jennifer A. Smith, K. Roman‐Torres, Sri Devineni, A. Craig, J. Mascarenhas   +25 more
semanticscholar   +1 more source

The Calreticulin gene and myeloproliferative neoplasms [PDF]

, 2016
The Philadelphia negative myeloproliferative neoplasms include polycythaemia vera (PV), essential thrombocytopenia (ET) and primary myelofibrosis (PMF).
Clinton, Aoibhinn, McMullin, Mary Frances   +1 more
core   +1 more source

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis

British Journal of Haematology, EarlyView.
Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan, Imran Omerdeen, Bethan Psaila   +2 more
wiley   +1 more source

Primary myelofibrosis with increased haemoglobin concentration at presentation

British Journal of Haematology, EarlyView.
Subjects with primary myelofibrosis and elevated haemoglobin levels at diagnosis tend to have longer survival rates (OS) and blast transformation‐free survival (BTFS) than those with normal or reduced haemoglobin levels. Summary One hundred of 963 consecutive registrants with primary myelofibrosis (PMF) in the Pavia‐CSM database had haemoglobin ...
Giovanni Barosi, Rita Campanelli, Paolo Catarsi, Carlotta Abbà, Adriana Carolei, Margherita Massa, Annalisa De Silvestri, Robert Peter Gale, Vittorio Rosti   +8 more
wiley   +1 more source

Correlation between Primary Myelofibrosis and the Association of Portal Thrombosis with Portal-Biliary Cavernoma: US, MDCT, and MRI Features

Journal of Gastrointestinal and Abdominal Radiology, 2021
Objective Myelofibrosis is a rare chronic myelolymphoproliferative disease and is associated with increased risk of venous thromboembolism. The objective of this study is to retrospectively evaluate patients with primary myelofibrosis who underwent ...
Marco Di Girolamo, Stefania Galassi, Salvatore Merola, Paolo Bonome, Esmeralda Conte, Elsa Iannicelli   +5 more
doaj   +1 more source

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Cancer, 2019
After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before the receipt of ruxolitinib may predict drug discontinuation in patients with ...
F. Palandri, M. Breccia, M. Bonifacio, N. Polverelli, E. Elli, G. Benevolo, M. Tiribelli, E. Abruzzese, A. Iurlo, F. Heidel, M. Bergamaschi, A. Tieghi, M. Crugnola, F. Cavazzini, G. Binotto, A. Isidori, N. Sgherza, C. Bosi, B. Martino, R. Latagliata, G. Auteri, L. Scaffidi, D. Griguolo, M. Trawinska, D. Cattaneo, L. Catani, M. Krampera, R. Lemoli, A. Cuneo, G. Semenzato, R. Foà, F. Di Raimondo, D. Bartoletti, M. Cavo, G. Palumbo, N. Vianelli   +35 more
semanticscholar   +1 more source

Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

Blood Advances, 2021
Key Points Peritransplantation ruxolitinib was safe and well tolerated in patients with myelofibrosis, with MTD determined as 10 mg twice daily.
H. Ali, N. Tsai, T. Synold, S. Mokhtari, Weimin Tsai, J. Palmer, T. Stiller, A. Salhotra, S. Rahmanuddin, V. Pullarkat, J. Cai, A. Stein, S. Forman, G. Marcucci, M. Mei, D. Snyder, R. Nakamura   +16 more
semanticscholar   +1 more source

miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6 [PDF]

, 2017
Primary myelofibrosis (PMF) is a chronic Philadelphia-negative myeloproliferative neoplasm characterized by hematopoietic stem cell-derived clonal myeloproliferation, involving especially the megakaryocyte lineage.
Barosi, Giovanni, Bianchi, Elisa, Guglielmelli, Paola, Manfredini, Rossella, Norfo, Ruggiero, Pennucci, Valentina, Prudente, Zelia, Rontauroli, Sebastiano, Rossi, Chiara, Rosti, Vittorio, Ruberti, Samantha, Salati, Simona, Tagliafico, Enrico, Vannucchi, Alessandro, Zini, Roberta   +14 more
core   +1 more source

UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI)

British Journal of Haematology, EarlyView.
Summary In allogeneic haematopoietic stem cell transplantation (HSCT), important clinical decisions depend upon assessment of chimerism, including immunosuppressant dosing and donor lymphocyte infusions (DLI), which in turn can have major impacts on disease control, graft‐versus‐host disease (GVHD), immunity and ultimately patient survival.
Andrew Clark, Hazel Clouston, Kanchan Rao, Najeem Folarin, Josu De la Fuente, Angela Hamblin, Eduardo Olavarria, Debbie Richardson, Polly Talley, Victoria Potter, Justin Loke, Terri McVeigh, John Snowden   +12 more
wiley   +1 more source